PHAT
Phathom Pharmaceuticals, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website athompharma.com
- Employees(FY) 112
- ISIN US71722W1071
Performance
+4.17%
1W
+4.35%
1M
+62.75%
3M
+79.28%
6M
+97.15%
YTD
+126.42%
1Y
Profile
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Technical Analysis of PHAT 2024-11-06
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-06 19:00
- 2024-11-06 07:21
- 2024-11-04 08:00
- 2024-11-03 19:00
- 2024-11-01 09:36
- 2024-10-28 08:00
- 2024-10-27 20:00
- 2024-10-27 12:00
- 2024-10-27 00:00
- 2024-08-29 08:00
- 2024-08-28 20:00
- 2024-08-19 09:14
- 2024-08-19 08:00
- 2024-08-18 20:00
- 2024-08-08 09:20
- 2024-08-08 08:00
- 2024-08-07 20:00
- 2024-07-30 08:00
- 2024-07-29 20:00
- 2024-07-29 07:59
- 2024-07-28 19:59
- 2024-07-18 10:24
- 2024-07-18 08:38
Daily – Vickers Top Buyers & Sellers for 07/18/2024(Argus Research)
- 2024-07-18 08:00
- 2024-07-17 20:00
- 2024-06-09 07:00
- 2024-06-08 19:00
- 2024-06-07 06:17
- 2024-06-06 18:17
- 2024-05-28 08:00
Page 1 of 6
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.